Biomea Fusion logo

Biomea FusionNASDAQ: BMEA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 April 2021

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$358.76 M
-76%vs. 3y high
61%vs. sector
-vs. 3y high
-vs. sector
-74%vs. 3y high
81%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 31 Oct 2024 23:40:40 GMT
$9.90-$0.30(-2.94%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

BMEA Latest News

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Law Violations
accesswire.com27 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm
accesswire.com26 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
globenewswire.com21 October 2024 Sentiment: POSITIVE

Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions
accesswire.com19 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Biomea Fusion, Inc. (BMEA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
accesswire.com16 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Law Violations
accesswire.com15 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Biomea Fusion, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - BMEA
accesswire.com15 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Biomea Fusion, Inc. (BMEA)
accesswire.com14 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions
accesswire.com13 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm
accesswire.com12 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

What type of business is Biomea Fusion?

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

What sector is Biomea Fusion in?

Biomea Fusion is in the Healthcare sector

What industry is Biomea Fusion in?

Biomea Fusion is in the Biotechnology industry

What country is Biomea Fusion from?

Biomea Fusion is headquartered in United States

When did Biomea Fusion go public?

Biomea Fusion initial public offering (IPO) was on 16 April 2021

What is Biomea Fusion website?

https://biomeafusion.com

Is Biomea Fusion in the S&P 500?

No, Biomea Fusion is not included in the S&P 500 index

Is Biomea Fusion in the NASDAQ 100?

No, Biomea Fusion is not included in the NASDAQ 100 index

Is Biomea Fusion in the Dow Jones?

No, Biomea Fusion is not included in the Dow Jones index

When was Biomea Fusion the previous earnings report?

No data

When does Biomea Fusion earnings report?

The next expected earnings date for Biomea Fusion is 28 March 2025